Please assess the completion status of the following clinical trial:

Trial Title: Masitinib in Combination With Riluzole for the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Main inclusion criteria:~1. Familial or sporadic ALS~2. Patient diagnosed with probable of definite ALS~3. Patient treated with a stable dose of riluzole (100 mg/day) for at least 30 days prior to screening~Exclusion Criteria:~1. Patient who underwent tracheostomy and/or gastrostomy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Masitinib (3.0) & Riluzole (Type: EXPERIMENTAL): masitinib 3 mg/kg/day + riluzole
- Masitinib (4.5) & Riluzole (Type: EXPERIMENTAL): masitinib 4.5 mg/kg/day (2) + riluzole
- Placebo & Riluzole (Type: PLACEBO_COMPARATOR): Matched placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).